PRVB Provention Bio Inc.

3.8
0  0%
Previous Close 3.8
Open 3.85
Price To Book 2.9
Market Cap 141973936
Shares 37,361,562
Volume 112,470
Short Ratio
Av. Daily Volume 67,373

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b top-line data May 8, 2019 noted primary safety and tolerability endpoint met but efficacy and other secondary endpoints were not met.
PRV-300
Ulcerative Colitis
Phase 3 trial initiation announced April 9, 2019. Enrollment to be completed in 2020.
PRV-031 (teplizumab)
Type 1 diabetes
Phase 2a data due 4Q 2019.
PRV-6527
Crohn's disease
Phase 2b trial to commence 2020.
PRV-015
Celiac disease
Phase 1b to commence 2H 2019.
PRV-3279
Systemic Lupus Erythematosus (SLE) and Lupus nephritis (LN)

Latest News

  1. The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut
  2. Provention Bio Reports First Quarter 2019 Financial Results
  3. Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis
  4. Provention Bio Completes Enrollment of Phase 2a PRINCE Clinical Trial with PRV-6527 in Patients with Moderate to Severe Crohn's Disease
  5. Provention Bio, Inc. (PRVB) Shares March Higher, Can It Continue?
  6. Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes
  7. Provention Bio Announces Key Additions to its Senior Management Team
  8. Provention Bio Appoints Jeffrey Bluestone, PhD, to Board of Directors
  9. Provention Bio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
  10. Provention Bio to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 19, 2019
  11. Provention Bio To Present at 8th Annual Leerink Partners Global Healthcare Conference
  12. Provention Bio Receives Notice of Allowance from United States Patent and Trademark Office for Patent on Multi-Strain Coxsackievirus B Vaccine for Preventing or Treating Type 1 Diabetes (T1D)
  13. Provention Bio Announces Publication in "Expert Review of Vaccines" Describing the Scientific Rationale for Developing a Vaccine for Type 1 Diabetes by Targeting Coxsackievirus B
  14. Are Insiders Buying Provention Bio, Inc. (NASDAQ:PRVB) Stock?
  15. Provention Bio Joins the C-Path Type 1 Diabetes (T1D) Consortium
  16. Provention Bio Reports Third Quarter 2018 Financial Results and Provides Business Update
  17. Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease
  18. Provention Bio Announces Completion of Enrollment of Phase 1b Clinical Trial of PRV-300 in Moderate-to-Severe Ulcerative Colitis
  19. Provention Bio To Present at 2018 Janney Healthcare Conference
  20. Provention Bio Appoints Accomplished Biotech Executive, Chip Catlin, to its Board of Directors